The pharmacokinetics of xamoterol in liver disease
| Autor: | W Bastain, D P Nicholls, Robin G. Shanks, J P McCann, A J Taggart |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male medicine.medical_specialty Xamoterol Radioimmunoassay Administration Oral Biological Availability Blood Pressure Partial agonist Propanolamines Electrocardiography chemistry.chemical_compound Liver disease Pharmacokinetics Heart Rate Oral administration Internal medicine Heart rate Humans Medicine Pharmacology (medical) Aged Pharmacology business.industry Liver Diseases Middle Aged medicine.disease Blood pressure Endocrinology chemistry Heart failure Injections Intravenous Female business Research Article |
| Zdroj: | British Journal of Clinical Pharmacology. 28:718-721 |
| ISSN: | 0306-5251 |
| DOI: | 10.1111/j.1365-2125.1989.tb03566.x |
| Popis: | The pharmacokinetics of xamoterol, a beta 1-adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age- and sex-matched normal controls. No significant differences were observed after the oral administration of xamoterol 200 mg. The low bioavailability of xamoterol was confirmed (6.1% in patients, 6.9% in controls). After i.v. xamoterol 0.2 mg kg-1, no significant differences between the groups were observed. A small increase in the terminal plasma elimination half-life (t1/2) was observed in patients when compared with controls (15.3 +/- 6.4 vs 8.4 +/- 2.8 h, mean +/- s.d., P = 0.08). Renal clearance accounted for about 50% of total clearance in patients and about 30% in controls. It is suggested that in patients with heart failure, hepatic dysfunction would probably not influence xamoterol disposition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text